Dry! Mercadon publishes an overview of the tumor product pipeline.

On September 22nd, Mercedon held an online investor conference after the ESMO 2020 conference, simply summarizing the data released at the conference and showing the progress of the company's other tumor pipelines.
has a number of early assets in the tumor pipeline, including more than 20 immunotherapy.
, in addition to introducing Keytruda at the investor conference, Mercadon introduced Olapali (PARP inhibitors), Vibostolimab (TIGIT monomaide), MK-4830 (ILT4 monoantigen) and MK-6482 (HIF-2 alpha inhibitors).
,500 million in sales in the first half of 2020 and is expected to exceed $12 billion for the full year.
2 PPTS at the investor conference showed the efficacy of Keytruda as a single or co-administration drug in more than 30 tumor types.
in the future development of Keytruda, Mercator will primarily benefit more cancer patients by exploring combination therapies and new complementary/assisted therapies.
, Keytruda currently has more than 1,300 clinical trials underway worldwide, including more than 900 combined drug studies, more than 110 complementary/new complementary treatment early treatment studies, and more than 90 registered clinical trials.
ESMO 2020 conference, Mercedon released a series of new, long-term follow-up data and early research data for the oncology field.
, the KEYNOTE-590 study showed that Keytruda combined chemotherapy for first-line treatment of esophageal cancer reduced the risk of death by 27% (HR 0.73) compared to chemotherapy, regardless of PD-L1 status.
LEAP-004 study, Keytruda co-lunvatinil may offer new treatments for patients with PD-1/L1 incurable melanoma.
the study showed that the keytruda-lenphatini monotherapy had ORR of 21.4% in the overall population, and or 31.0% in patients who had received PD-1/L1 monoantigen and CTLA-4 monoantigen therapy.
long-term benefits, Mercedon published three long-term follow-up data for Keytruda's treatment of NSCLC, head and neck cancer and melanoma.
In the KEYNOTE-024 study, patients with PD-L1 expression (TPS-gt;50%), metastasis NSCLC, who received keytruda single-drug first-line treatment, had a five-year survival rate twice that of chemotherapy patients, and a continuous response time was almost five times that of chemotherapy patients (29.1 vs. 6.3 months).
3-year follow-up data from the KEYNOTE-048 study showed that in patients with CPS≥1, Keytruda combined chemotherapy was significantly longer than the median OS in the EXTREME protocol (13.6 vs. 10.6 months, HR 0.64).
3-year follow-up data from the KEYNOTE-054 study showed that Keytruda single-drug as an ancillary therapy could lead to continuous improvement of PFS in patients with Stage III melanoma.
long-term follow-up data for Olapali show that it benefits OS for patients with BRCA1/2 or ATM mutations, and PFS for advanced ovarian cancer with BRCA mutations.
, five-year follow-up data from the Phase III SOLO-1 study showed that Olapali reduced the patient's risk of disease progression or death by 67 percent and extended PFS to 56 months, compared with 13.8 months in the placebo group.
addition, early study data from Vibostolimab (TIGIT monoantial) in the treatment of patients with advanced NSCLC in Keytruda published by Merca East showed that patients had ORR of 29%, of which TPS>1% of patients had ORR of 46%.
Phase I data showing that patients with ORR were 24 percent and 5 out of 11 patients who had previously been treated with PD-1 responded (45 percent), according to Phase I data from the MK-4830 (ILT4 monoantigen) joint Keytruda treatment.
latest research data on MK-6482 (HIF-2 alpha inhibitors) used to treat VHL-related renal cell carcinoma (cRCC) and non-RCC diseases also show exciting overall response rates.
The drug was 36.1% ORR in VHL-related RCC patients, 63.9% in patients with pancreatic lesions, 30.2% in patients with central nervous system hemangioma, and 93.8% of patients with retinal lesions achieved better response or remission.
in the field of oncology, Mercado has acquired a number of research products through cooperative development, trading licensing and acquisition.
, for example, recently paid $4.5 billion for two product development interests, including LIV-1 ADC, from Seattle Genetics, which Mercerton said it would explore the efficacy of LIV-1 ADC's joint Keytruda treatment for trisulpheric breasts and other solid tumors.
.